Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | DRD3 | P35462 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322004 | 0.76 | HTR2C (0.49) | HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL1698462 | 0.74 | DRD2 (0.48) | HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL5368588 | 0.72 | ADRB1 (0.65) | DRD2HTR2ADRD3 | |
| SCHEMBL1698905 | 0.72 | DRD2 (0.71) | DRD2HTR2ADRD3 | |
| SCHEMBL1698913 | 0.71 | DRD2 (0.70) | DRD2HTR2ADRD3 | |
| SCHEMBL31354869 | 0.71 | HTR2C (0.48) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL27237927 | 0.71 | ADRB1 (0.63) | DRD2HTR2ADRD3 | |
| SCHEMBL1698465 | 0.71 | DRD2 (0.48) | HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL12074824 | 0.70 | DRD2 (0.71) | DRD2HTR2ADRD3 | |
| SCHEMBL14874310 | 0.70 | DRD2 (0.71) | DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582705-B1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8586579-B2 | Anellated pyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | HTR2C 10/4885DRD2 78/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.